Cargando…

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Jeong, Chaiho, Kim, Jinyoung, Lim, Yejee, Ha, Jeonghoon, Kang, Moo Il, Baek, Ki-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Bone and Mineral Research 2022
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760771/ https://www.ncbi.nlm.nih.gov/pubmed/36529871 http://dx.doi.org/10.11005/jbm.2022.29.4.279

Ejemplares similares

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2021)

Effect of Denosumab on Bone Density in Postmenopausal Osteoporosis: A Comparison with and without Calcium Supplementation in Patients on Standard Diets in Korea
por: Jeong, Chaiho, et al.
Publicado: (2023)

The efficacy of denosumab in Korean male patients with osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Roles of Follicle-Stimulating Hormone on Bone Metabolism in Late Postmenopausal Women
por: Jeong, Chaiho, et al.
Publicado: (2022)

Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
por: Jeong, Chaiho, et al.
Publicado: (2023)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Romosozumab for osteoporosis
Publicado: (2021)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
por: Baek, Ki-Hyun, et al.
Publicado: (2021)

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Longitudinal Change in Trabecular Bone Score during and after Treatment of Osteoporosis in Postmenopausal Korean Women
por: Shin, Mi-Seon, et al.
Publicado: (2017)

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
por: Lim, Sian Yik
Publicado: (2022)

Serum 25-hydroxyvitamin D and Metabolic Parameters in Healthy Korean Adults: Korean National Health and Nutrition Examination Survey VI
por: Ha, Jeonghoon, et al.
Publicado: (2021)

Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study (Endocrinol Metab 2020;35:925–32, Chaiho Jeong et al.)
por: Jeong, Chaiho, et al.
Publicado: (2021)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives
por: Lim, Sian Yik, et al.
Publicado: (2022)

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study
por: Jeong, Chaiho, et al.
Publicado: (2020)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis
por: Trepanowski, Nicole, et al.
Publicado: (2023)

Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study
por: Kim, Jinyoung, et al.
Publicado: (2023)

Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
por: Tian, Aixian, et al.
Publicado: (2021)

Erratum to: MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones
por: De-Ugarte, Laura, et al.
Publicado: (2017)

Heart Rate Variability in Postoperative Patients with Nonfunctioning Pituitary Adenoma
por: Ha, Jeonghoon, et al.
Publicado: (2021)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

Effects of Bazedoxifene/Vitamin D Combination Therapy on Serum Vitamin D Levels and Bone Turnover Markers in Postmenopausal Women with Osteopenia: A Randomized Controlled Trial
por: Jeong, Chaiho, et al.
Publicado: (2023)

Body mass index at the crossroads of osteoporosis and type 2 diabetes
por: Ha, Jeonghoon, et al.
Publicado: (2020)

Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial
por: Kim, Jinyoung, et al.
Publicado: (2022)

Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
por: Baek, Han-sang, et al.
Publicado: (2022)

Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients
por: Jeong, Chaiho, et al.
Publicado: (2020)

Oxidative Stress and Bone Resorption Interplay as a Possible Trigger for Postmenopausal Osteoporosis
por: Cervellati, Carlo, et al.
Publicado: (2014)

Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2015)

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
por: Dempster, David W, et al.
Publicado: (2021)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_st4c85ufm64u9hgfra5fe9rfrr